Dor Avi, Pauly Mark V, Eichleay Margaret A, Held Philip J
George Washington University, School of Public Health and Health Services, Washington, DC, USA.
Int J Health Care Finance Econ. 2007 Sep;7(2-3):73-111. doi: 10.1007/s10754-007-9024-9.
End-stage renal disease (ESRD) is a debilitating, costly, and increasingly common condition. Little is known about how different financing approaches affect ESRD outcomes and delivery of care. This paper presents results from a comparative review of 12 countries with alternative models of incentives and benefits, collected under the International Study of Health Care Organization and Financing, a substudy within the Dialysis Outcomes and Practice Patterns Study. Variation in spending per ESRD patient is relatively small, but correlated with overall per capita health care spending. Remaining differences in costs and outcomes do not seem strongly linked to differences in incentives.
终末期肾病(ESRD)是一种使人衰弱、成本高昂且日益常见的病症。对于不同的融资方式如何影响ESRD的治疗结果和医疗服务的提供,人们知之甚少。本文展示了对12个国家进行比较性综述的结果,这些国家采用了不同的激励和福利模式,数据收集自国际医疗保健组织与融资研究,该研究是透析结果与实践模式研究中的一项子研究。ESRD患者人均支出的差异相对较小,但与人均总体医疗保健支出相关。成本和结果方面的剩余差异似乎与激励措施的差异没有紧密联系。